PRO-ALPRAZOLAM 0.5 MG — DIN 01908170
ALPRAZOLAM : 0.5 MG · PRO DOC LIMITEE · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is PRO-ALPRAZOLAM?
PRO-ALPRAZOLAM 0.5 MG contains ALPRAZOLAM : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 01908170, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Mar-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PRO-ALPRAZOLAM used for?
Management of Anxiety Disorders, short-term relief of excessive anxiety, Generalized Anxiety Disorder (GAD), and Panic Disorder with or without Agoraphobia. (Max 200 chars)
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Alprazolam cost around the world?
Alprazolam is listed on 18 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Spain | PVP con IVA (public price) | 71 | 71 | EUR███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 5 | 60 | BRL███.██ |
| United States | acquisition | 4 | 60 | USD███.██ |
| Sweden | AIP (pharmacy purchase price) | 6 | 42 | SEK███.██ |
| South Africa | single exit price | 30 | 41 | ZAR███.██ |
| Czechia | max producer price (ex-factory) | 7 | 34 | CZK███.██ |
| Luxembourg | reimbursement | 27 | 27 | EUR███.██ |
| Romania | max producer price | 15 | 21 | RON███.██ |
| Hungary | producer price (ex-factory) | 12 | 16 | HUF███.██ |
| Slovakia | categorised final price | 15 | 15 | EUR███.██ |
| Greece | producer price (ex-factory) | 9 | 9 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 8 | EUR███.██ |
| Saudi Arabia | public | 6 | 8 | SAR███.██ |
| Bahrain | retail (max) | 1 | 7 | BHD███.██ |
| United Arab Emirates | public | 3 | 5 | AED███.██ |
| Australia | ex-manufacturer | 5 | 5 | AUD███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 4 | NOK███.██ |
| Morocco | PPV (public price) | 2 | 3 | MAD███.██ |
436 pack listings across 223 brand entries and 16 price bases, refreshed 08 Sep 2026. Ranges span every Alprazolam pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Alprazolam in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Alprazolam, across 50 DINs, of which 13 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 4 | 4 | APO-ALPRAZ, APO-ALPRAZ TS | Sourceable in Canada |
| BGP PHARMA ULC | 4 | 4 | XANAX, XANAX TS | Sourceable in Canada |
| PRO DOC LIMITEE | 4 | 3 | PRO-ALPRAZOLAM, PRO-ALPRAZOLAM TS | Sourceable in Canada |
| TEVA CANADA LIMITED | 4 | 2 | NTP-ALPRAZOLAM, TEVA-ALPRAZOLAM | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 12 | 0 | ALPRAZOLAM, JAMP ALPRAZOLAM, JAMP-ALPRAZOLAM | No marketed DIN |
| LABORATOIRE RIVA INC. | 6 | 0 | RIVA-ALPRAZOLAM, RIVA-ALPRAZOLAM 0.25 MG, RIVA-ALPRAZOLAM 0.5 MG | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 4 | 0 | MYLAN-ALPRAZOLAM | No marketed DIN |
| NATCO PHARMA (CANADA) INC | 4 | 0 | NAT-ALPRAZOLAM | No marketed DIN |
| NU-PHARM INC | 2 | 0 | NU-ALPRAZ TAB 0.25MG, NU-ALPRAZ TAB 0.5MG | No marketed DIN |
| PREMPHARM INC | 2 | 0 | ALPRAZOLAM TABLETS 0.25, ALPRAZOLAM TABLETS 0.5MG | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 2 | 0 | RATIO-ALPRAZOLAM | No marketed DIN |
| SANIS HEALTH INC | 2 | 0 | ALPRAZOLAM | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text beyond tablet strengths (0.25 mg, 0.5 mg, 1.0 mg, 2 mg). |
| Storage | Not explicitly detailed in provided text (standard summary section mentions 'Storage and Stability' on page 23, which is not included in the snippet). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Alprazolam |
|---|---|
| ATC code | N05BA12 |
| AHFS class | 28:24.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01908170 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1908170 |
| Brand name | PRO-ALPRAZOLAM |
| Generic / active ingredient | ALPRAZOLAM : 0.5 MG |
| Market authorization holder | PRO DOC LIMITEE |
| Health Canada schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05BA12 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05BA |
| Current status | MARKETED |
| Status date | 22-Mar-2022 |
| Original market date | 1991-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Anxiety: 0.25 mg 2-3 times daily, max 3 mg/day. Panic: 0.5 mg 3 times daily, may increase. Discontinue by tapering no more than 0.5 mg every 3 days. Administer at lowest effective dose.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to benzodiazepines; myasthenia gravis; severe hepatic or respiratory insufficiency; sleep apnea; acute narrow angle glaucoma; co-administration with ketoconazole or itraconazole.
Warnings and precautions
Risk of addiction, abuse, misuse; severe withdrawal/seizures if stopped abruptly; profound sedation/death if used with opioids; risk of falls/fractures in elderly. (Max 200 chars)
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
13 of 50 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ALPRAZ | 1 MG | TABLET | APOTEX INC | MARKETED | 02243611 |
| APO-ALPRAZ | 0.25 MG | TABLET | APOTEX INC | MARKETED | 00865397 |
| APO-ALPRAZ | 0.5 MG | TABLET | APOTEX INC | MARKETED | 00865400 |
| APO-ALPRAZ TS | 2 MG | TABLET | APOTEX INC | MARKETED | 02243612 |
| PRO-ALPRAZOLAM | 0.25 MG | TABLET | PRO DOC LIMITEE | MARKETED | 01908189 |
| PRO-ALPRAZOLAM | 1 MG | TABLET | PRO DOC LIMITEE | MARKETED | 02248706 |
| TEVA-ALPRAZOLAM | 0.25 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 01913484 |
| TEVA-ALPRAZOLAM | 0.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 01913492 |
| XANAX | 0.25 MG | TABLET | BGP PHARMA ULC | MARKETED | 00548359 |
| XANAX | 1 MG | TABLET | BGP PHARMA ULC | MARKETED | 00723770 |
2 · Same class — other molecules in ATC N05BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lorazepam | APO-LORAZEPAM · ATIVAN · ATIVAN INJ 4MG/ML · ATIVAN INJECTION LIQ 4MG/ML · +21 more | 53 | 17 | Yes |
| Alprazolam | ALPRAZOLAM · ALPRAZOLAM TABLETS 0.25 · ALPRAZOLAM TABLETS 0.5MG · APO-ALPRAZ · +17 more | 50 | 13 | Yes |
| Oxazepam | APO-OXAZEPAM · BIO-OXAZEPAM · NOVOXAPAM TAB 10MG · NOVOXAPAM TAB 15MG · +17 more | 31 | 9 | Yes |
| Diazepam | BIO-DIAZEPAM · DIASTAT · DIAZEMULS · DIAZEPAM · +23 more | 38 | 8 | Yes |
| Bromazepam | ALTI-BROMAZEPAM 1.5MG TABLETS · ALTI-BROMAZEPAM 3MG TABLETS · ALTI-BROMAZEPAM 6MG TABLETS · APO-BROMAZEPAM · +14 more | 24 | 4 | Yes |
| Clorazepate Potassium | CLORAZEPATE · NOVO-CLOPATE CAP 15MG · NOVO-CLOPATE CAP 3.75MG · NOVO-CLOPATE CAP 7.5MG · +3 more | 9 | 3 | Yes |
| Clobazam | APO-CLOBAZAM · CLOBAZAM-10 · DOM-CLOBAZAM · FRISIUM TAB 10MG · +6 more | 10 | 2 | Yes |
| Chlordiazepoxide | CHLORDIAZEPOXIDE · CHLORDIAZEPOXIDE CAP 10MG · CHLORDIAZEPOXIDE CAP 5MG · CHLORDIAZEPOXYDE 25 CAP · +10 more | 16 | 1 | Yes |
| Ketazolam | LOFTRAN CAP 30MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05BE | Buspirone | 25 | 7 |
| N05BB | Hydroxyzine | 29 | 5 |
| N05BC | Meprobamate | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PRO-ALPRAZOLAM called?
The same molecule, Alprazolam, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ALPRAZOLAM | Latin | Brazil |
| XANAX | Latin | Bahrain, Czechia, Morocco |
| Xanor® | Latin | Sweden |
| Alprazolam Grindeks | Latin | Czechia, Sweden |
| Alprazolam Krka d.d. | Latin | Sweden |
| FRONTAL | Latin | Brazil |
| TRANQUINAL | Latin | Brazil |
| Alprazolam Krka | Latin | Sweden |
| Alprazolam Orion | Latin | Sweden |
| FRONTIN | Latin | Czechia |
| XANAX SR | Latin | Czechia |
| Xanor® Depot | Latin | Sweden |
| APRAZ | Latin | Brazil |
| Xanor | Latin | Norway |
| ALPROX | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.